Fig 1.

(A) Frequency and type of various molecular alterations found among 60 individuals with lymphoid malignancies. Only the 15 most common alterations are shown. The full list of alterations is shown in the Data Supplement. (IGH refers to IGH translocations that involve a partner gene.) (B) The number of patients with the designated number of total alterations and the number of patients with the designated number of potentially actionable alterations by an US Food and Drug Administration (FDA) –approved drug (on or off label).